The Impact of VEGF Inhibition on Clinical Outcomes in Patients With Advanced Non-Small Cell Lung Cancer Treated With Immunotherapy: A Retrospective Cohort Study.

Front Oncol · 2021 · PMC8194394 · PMID 34123822

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Among the 98 patients who discontinued ICI treatment, previous treatment with anti-VEGF agents (n = 34) showed a trend toward prolonged OS compared to no previous treatment with anti-VEGF agents (n = 64) [median OS 20.1 months (95% CI 12.7-26.6) and 11.0 months (95% CI 6.6-15.5), respectively; p = 0.216] and post-ICI survival time [HR: 0.68 (95% CI: 0.42-1.09), p = 0.027] ( Figures 4A, B ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.